97 related articles for article (PubMed ID: 16609038)
1. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
[TBL] [Abstract][Full Text] [Related]
2. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
Giffin MJ; Cooke K; Lobenhofer EK; Estrada J; Zhan J; Deegen P; Thomas M; Murawsky CM; Werner J; Liu S; Lee F; Homann O; Friedrich M; Pearson JT; Raum T; Yang Y; Caenepeel S; Stevens J; Beltran PJ; Canon J; Coxon A; Bailis JM; Hughes PE
Clin Cancer Res; 2021 Mar; 27(5):1526-1537. PubMed ID: 33203642
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.
Caracciolo D; Riillo C; Ballerini A; Gaipa G; Lhermitte L; Rossi M; Botta C; Duroyon E; Grillone K; Gallo Cantafio ME; Buracchi C; Alampi G; Gulino A; Belmonte B; Conforti F; Golino G; Juli G; Altomare E; Polerà N; Scionti F; Arbitrio M; Iannone M; Martino M; Correale P; Talarico G; Ghelli Luserna di Rorà A; Ferrari A; Concolino D; Sestito S; Pensabene L; Giordano A; Hildinger M; Di Martino MT; Martinelli G; Tripodo C; Asnafi V; Biondi A; Tagliaferri P; Tassone P
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597219
[TBL] [Abstract][Full Text] [Related]
4. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
[TBL] [Abstract][Full Text] [Related]
5. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.
Zhou Y; Zong H; Han L; Xie Y; Jiang H; Gilly J; Zhang B; Lu H; Chen J; Sun R; Pan Z; Zhu J
J Exp Clin Cancer Res; 2020 May; 39(1):87. PubMed ID: 32398042
[TBL] [Abstract][Full Text] [Related]
6. Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells.
Froesch BA; Stahel RA; Zangemeister-Wittke U
Cancer Immunol Immunother; 1996 Jan; 42(1):55-63. PubMed ID: 8625367
[TBL] [Abstract][Full Text] [Related]
7. A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
Fisher TS; Hooper AT; Lucas J; Clark TH; Rohner AK; Peano B; Elliott MW; Tsaparikos K; Wang H; Golas J; Gavriil M; Haddish-Berhane N; Tchistiakova L; Gerber HP; Root AR; May C
Cancer Immunol Immunother; 2018 Feb; 67(2):247-259. PubMed ID: 29067496
[TBL] [Abstract][Full Text] [Related]
8. Development of a bispecific F(ab')2 conjugate against the complement receptor CR3 of macrophages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage-mediated tumor cytotoxicity.
Somasundaram C; Arch R; Matzku S; Zöller M
Cancer Immunol Immunother; 1996 Jul; 42(6):343-50. PubMed ID: 8830737
[TBL] [Abstract][Full Text] [Related]
9. T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies.
Garrido G; Lorenzano P; Sánchez B; Beausoleil I; Alonso DF; Pérez R; Fernández LE
Cancer Immunol Immunother; 2007 Nov; 56(11):1701-10. PubMed ID: 17415565
[TBL] [Abstract][Full Text] [Related]
10. Ex-vivo CS1-OKT3 dual specific bivalent antibody-armed effector T cells mediate cellular immunity against multiple myeloma.
Awuah D; Li L; Williams L; Urak R; Kujawski M; Forman SJ; Shively JE; Wang X
Sci Rep; 2023 Nov; 13(1):20853. PubMed ID: 38012196
[TBL] [Abstract][Full Text] [Related]
11. A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a "βγ-only" interleukin-2 variant.
Jiang Y; Chen C; Liu Y; Wang R; Feng C; Cai L; Chang S; Zhao L
Front Immunol; 2024; 15():1369376. PubMed ID: 38638426
[TBL] [Abstract][Full Text] [Related]
12. Tarlatamab Shows Promise in SCLC.
Cancer Discov; 2023 Dec; 13(12):2494. PubMed ID: 37877814
[TBL] [Abstract][Full Text] [Related]
13. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.
Suwanchiwasiri K; Phanthaphol N; Somboonpatarakun C; Yuti P; Sujjitjoon J; Luangwattananun P; Maher J; Yenchitsomanus PT; Junking M
Biomed Pharmacother; 2024 May; 175():116718. PubMed ID: 38744221
[TBL] [Abstract][Full Text] [Related]
14. Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2.
Zhou DD; Sun LP; Yu Q; Zhai XT; Zhang LW; Gao RJ; Zhen YS; Wang R; Miao QF
Int J Biol Macromol; 2023 Dec; 253(Pt 6):127105. PubMed ID: 37769779
[TBL] [Abstract][Full Text] [Related]
15. Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles.
Yang YS; Moynihan KD; Bekdemir A; Dichwalkar TM; Noh MM; Watson N; Melo M; Ingram J; Suh H; Ploegh H; Stellacci FR; Irvine DJ
Biomater Sci; 2018 Dec; 7(1):113-124. PubMed ID: 30444251
[TBL] [Abstract][Full Text] [Related]
16. Nucleolar protein TAAP1/
Döring M; Brux M; Paszkowski-Rogacz M; Guillem-Gloria PM; Buchholz F; Pisabarro MT; Theis M
Life Sci Alliance; 2024 Apr; 7(4):. PubMed ID: 38228372
[TBL] [Abstract][Full Text] [Related]
17. Small cell lung cancer cells express the late stage gBK tumor antigen: a possible immunotarget for the terminal disease.
Hoa NT; Ge L; Tajhya RB; Beeton C; Cornforth AN; Abolhoda A; Lambrecht N; DaCosta-Iyer M; Ouyang Y; Mai AP; Hong E; Shon J; Hickey MJ; Erickson KL; Kruse CA; Jadus MR
Am J Transl Res; 2014; 6(3):188-205. PubMed ID: 24936214
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager.
Gong N; Han X; Xue L; Billingsley MM; Huang X; El-Mayta R; Qin J; Sheppard NC; June CH; Mitchell MJ
Nat Biomed Eng; 2024 Feb; ():. PubMed ID: 38378820
[TBL] [Abstract][Full Text] [Related]
19. Author Correction: Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager.
Gong N; Han X; Xue L; Billingsley MM; Huang X; El-Mayta R; Qin J; Sheppard NC; June CH; Mitchell MJ
Nat Biomed Eng; 2024 Mar; ():. PubMed ID: 38491330
[No Abstract] [Full Text] [Related]
20. Correction: Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody.
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433715
[No Abstract] [Full Text] [Related]
[Next] [New Search]
